### The HIV Prevention Pipeline

#### In development: Preclinical and clinical
- Long-acting implants
- Preventive vaccines
- Multipurpose vaginal ring
- Long-acting vaginal ring
- Patches
- Douche
- Vaginal Film
- Vaginal Gel
- Vaginal/Mucosal inserts
- Broadly neutralizing antibodies
- Vaginal Film
- Vaginal Gel
- Vaginal/Mucosal inserts
- Broadly neutralizing antibodies

#### In development: Efficacy trials under way
- Long-acting injectable
- Daily oral PrEP\(^1\)
- Combo oral PrEP/OC
  - Possible dual pill to market by 2025.\(^2\)

#### Newly Approved and Recommended
- Dapivirine vaginal ring
- Long-acting injectable

#### Currently available
- HIV treatment for people living with HIV/U=U
- Male & female male condoms
- Voluntary medical male circumcision
- Syringe exchange programs
- Daily oral PrEP
- PEP

---

\(^1\) In Oct 2019, US FDA approved F/TAF for adults and adolescents who have no HIV risk from receptive vaginal sex; still in development for cisgender women.

\(^2\) Efficacy trials not required; bioequivalency of the two approved products when dosed together may be all that is required.